laura ramos vice president forrester research
DESCRIPTION
TRANSCRIPT
![Page 1: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/1.jpg)
ePedigree In Pharma — RFID Delays Mean More Work Lies AheadLaura Ramos
Vice President
Forrester Research
November 2, 2005. Call in at 10:55 p.m. Eastern Time
![Page 2: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/2.jpg)
Theme
However uncertain, the path to ePedigree compliance — and
benefits — starts now.
![Page 3: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/3.jpg)
Agenda
• RFID overview and pharma market perspective
• State of ePedigree adoption in pharma
• Benefits and road blocks
• A word about RFID vendors in pharma
• Processes likely to benefit in the future
• Best practices
![Page 4: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/4.jpg)
The RFID market is still very new . . .
Yes17%
No67%
Don't know16%
Base: 210 North American and European decision-makers
“During 2005, will your company purchase RFID technology?”
Retail and consumer products25%
Public sector22%
High tech14%
Other (nine industries)39%
Source: Forrester’s Business Technographics® November 2004 Benchmark Study
![Page 5: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/5.jpg)
. . . And suffering its share of disillusionment
• Perception that RFID is “that Wal-Mart thing”
• Limited understanding of RFID
• Belief that other types of data offer more near-term ROI
• Concerns — true and unfounded — about RFID and privacy
![Page 6: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/6.jpg)
Pharma definitions
► Pharmaceutical pedigree: record of a drug’s chain of custody, from the point of manufacture to the point of dispensing.
► ePedigree: electronic version of record.
![Page 7: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/7.jpg)
Why ePedigree?
• Counterfeit drug activity is rising sharply.
• State laws require pedigree starting in mid 2006 (ePedigree in 2007).
• FDA favors it.
• Consumers demand safer drugs.
Source: “Combating Counterfeit Drugs: A Report of the Food and Drug Administration” FDA annual update, May 19, 2005
![Page 8: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/8.jpg)
Firms united on safety, not drug pedigree
Base: 13 respondents from top pharmaceutical and life sciences companies
Source: September 21, 2005, Market Overview “Pharma Won’t Meet ePedigree Deadlines”
![Page 9: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/9.jpg)
Many factors affect ePedigree adoption
• Accelerators:
» Regulation compliance
» Quality control
» Law enforcement
» Inventory mgmt process improvements
» Need for real-world awareness
• Inhibitors:
» High cost
» Technology issues
» Weak business case
» Accepted use of parallel trade
» Lack of standards
» Conservatism
![Page 10: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/10.jpg)
Industry progress lags behind
• No full warehouse or data system in production
• $10B+ pharma firms can spend $60M on setup
• Wholesale distributors = $10M to $20M per year
• Falling back on paper
Base: 13 respondents from top pharmaceutical and life sciences companies
![Page 11: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/11.jpg)
Asymmetric cost/benefits impeded progress
![Page 12: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/12.jpg)
RFID benefits expected
Base: 13 respondents from top pharmaceutical and life sciences companies
Any expected
Most expected
12
10
9
9
4
2
2
1
3
5
3
2
Supply chain visibility
Greater safety/security
Regulatory compliance
Less theft, loss of product
Process improvement
Reduce compliance costs
Faster clinical trials/FDA submission
Lower cost of drug logistics
Which benefits expect to gain from ePedigree?
![Page 13: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/13.jpg)
Future RFID uses under consideration
Base: 13 respondents from top pharmaceutical and life sciences companies
6
6
4
4
3
2
2
1
1
0
0
Inventory and replenishment planning
Transportation management
Demand planning and forecasting
Order management and fulfillment
Long-term advert. and merchandising
Trade promotion management
Consumer segmt/retention mktg
Prod dev and new-item intro
Other (Submitted: cold chain management)
Pricing and revenue management
Assortment planning
For which other processes are you considering RFID use?
![Page 14: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/14.jpg)
Technical, cost, and complexity concerns dominate the pharma conversation
Base: 13 respondents from top pharmaceutical and life sciences companies
Rate the extent you agree or disagree with:
![Page 15: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/15.jpg)
Greatest challenges: data, cost
• Data:
» Data management and providing or receiving access to data collected
» Finding a way to manage and use all the data it will provide
» Getting good, solid, usable data (Reference to RFID read accuracy)
» Translating low-volume pilots into high-volume production
• Cost:
» Cost, people resources, and acceptance in industry.
» Determining how costs for implementation will be footed both internally and
externally.
– Internally, should it be funded by marketing or supply chain departments?
– Externally, how should costs be split between manufacturers, distributors, etc.?
![Page 16: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/16.jpg)
Greatest challenges: cooperation
• Cooperation:
» Getting the wholesalers and retailers involved in the sharing of product information through the supply chain.
» Getting agreement amongst trading partners on access to and use of data.
» Getting agreement from customers to accept and share data downstream.
![Page 17: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/17.jpg)
No one vendor provides full solution
SupplyScape, T3Ci, Cyclone Commerce
SAP, Oracle
3M, CCL, Northern Apex, Symbol, Tagsys, Texas Instruments, West Pharmaceuticals
Intel, Manhattan Associates, MeadWestVaco
AccentureCapgemini
HPIBM
UnisysPedigree
apps
Software platforms
RFID middleware
Hardware: tags, readers, labels
![Page 18: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/18.jpg)
Look at authentication as intermediate step
Source: August 19, 2005, Quick Take “TI, 3M, And VeriSign’s Rx For Drug Fraud”
![Page 19: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/19.jpg)
Beyond ePedigree compliance
• RFID benefits pharma distribution chain processes:
» Lot-level inventory management
» Controls to support regional markets and pricing
» Support recalls
» Clinical trials supply management
» Adverse drug interactions warnings/notification
» Integration with bedside dispensing to generate clinical data
![Page 20: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/20.jpg)
Pharmacy: reducing dispensing errors
![Page 21: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/21.jpg)
Medical device, hospital management
![Page 22: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/22.jpg)
Patient compliance?
Prototype AutoID computers on a dime
![Page 23: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/23.jpg)
Pharma RFID tipping point by end of decade
Source: September 21, 2005, Market Overview “Pharma Won’t Meet ePedigree Deadlines”
![Page 24: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/24.jpg)
Withstanding current RFID environment
• Break down communication barriers
» Establish timelines for serialization
» Review contracts
» Demonstrate authentication value
• Limit exposure to diverse state regulations
» Specific warehouses for FL
» Don’t mix RFID with non-RFID
» Top counterfeit products
» Fall back to paper
![Page 25: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/25.jpg)
Withstanding current RFID environment
• Experiment now, not later
» Be prepared to throw away initial projects.
» Don’t wait for partners or vendors to lead.
» Anticipate system validation work.
• Build business case
» Capture RFID specific costs
» Bring actual costs from pilots/regional centers to bargaining table
» Look for labor savings first
» Best outcome: authentication cost sharing in 18 months; ePedigree in 3 to 5 years
![Page 26: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/26.jpg)
Recommendations
• Expect states and FDA to sharpen focus on ePedigree.
• Focus on data mgmt m’ware and business rules.
• Work to even out distribution cost burdens.
• Put compliance effort/$$ back into business.
• Support local law enforcement — and pharmacies
![Page 27: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/27.jpg)
Selected bibliography
• September 21, 2005, Market Overview “Pharma Won’t Meet ePedigree Deadlines”
• August 19, 2005, Quick Take “TI, 3M, And VeriSign's Rx For Drug Fraud”
• July 7, 2005, Trends “Authentication, Not RFID, Will Make Drugs Safer”
• March 16, 2005, Forrester Collection “RFID: The Complete Guide”
• December 15, 2004, Trends “FDA Pushes RFID Agenda on Pharma”
• December 6, 2004, Best Practices “What Does The Bar-Code’s Past Reveal About RFID’s Future?”
• September 28, 2004, Trends “How RFID Adopters Buy Technology”
• March 1, 2004, Market Overview “RFID At What Cost?”
![Page 28: Laura Ramos Vice President Forrester Research](https://reader033.vdocuments.net/reader033/viewer/2022061208/5489195ab47959140d8b58ce/html5/thumbnails/28.jpg)
Laura Ramos
+1 408/327-4330
www.forrester.com
Thank you
Entire contents © 2005 Forrester Research, Inc. All rights reserved.